Entry |
|
Name |
Lenvatinib (USAN/INN) |
Formula |
C21H19ClN4O4
|
Exact mass |
426.1095
|
Mol weight |
426.853
|
Structure |
|
Simcomp |
|
Class |
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
Transporter substrate
DG01665 ABCB1 substrate
|
Remark |
Product (DG01362): | D09920<JP/US> |
|
Efficacy |
Antineoplastic, Receptor tyrosine kinase inhibitor |
Target |
|
Pathway |
|
Metabolism |
|
Interaction |
|
Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EX Other protein kinase inhibitors
L01EX08 Lenvatinib
D09919 Lenvatinib (USAN/INN)
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG01362 Lenvatinib
D09919 Lenvatinib
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG01362 Lenvatinib
D09919 Lenvatinib
Transporter substrate
DG01665 ABCB1 substrate
DG01362 Lenvatinib
D09919 Lenvatinib
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
FGFR family
FGFR
D09919 Lenvatinib (USAN/INN)
VEGFR family
VEGFR1 (FLT1)
D09919 Lenvatinib (USAN/INN)
VEGFR2 (KDR)
D09919 Lenvatinib (USAN/INN)
VEGFR3 (FLT4)
D09919 Lenvatinib (USAN/INN)
RET family
RET
D09919 Lenvatinib (USAN/INN)
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D09919
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D09919
Drug transporters
D09919
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG01362 Lenvatinib
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG01362 Lenvatinib
Transporter substrate
DG01665 ABCB1 substrate
DG01362 Lenvatinib
|
Other DBs |
|
KCF data |
ATOM 30
1 C8y C 8.9600 -18.7600
2 C8y C 8.9600 -20.1600
3 C8x C 10.1724 -20.8600
4 C8y C 11.3849 -20.1600
5 C8y C 11.3849 -18.7600
6 C8x C 10.1724 -18.0600
7 C8y C 12.5973 -20.8600
8 C8x C 13.8097 -20.1600
9 C8x C 13.8097 -18.7600
10 N5x N 12.5973 -18.0600
11 O2a O 12.5973 -22.2600
12 C8y C 13.8118 -22.9612
13 C8x C 13.8117 -24.3598
14 C8y C 15.0242 -25.0599
15 C8y C 16.2366 -24.3599
16 C8x C 16.2366 -22.9612
17 C8x C 15.0242 -22.2612
18 O2a O 7.7476 -18.0600
19 C5a C 7.7476 -20.8600
20 N1a N 6.5521 -20.1696
21 O5a O 7.7475 -22.2598
22 X Cl 15.0241 -26.4598
23 N1b N 17.4516 -25.0614
24 C5a C 18.6483 -24.3703
25 N1b N 19.8350 -25.0555
26 O5a O 18.6485 -22.9603
27 C1a C 6.5521 -18.7504
28 C1y C 21.0267 -24.3674
29 C1x C 22.4267 -24.3674
30 C1x C 21.7267 -23.1549
BOND 33
1 1 2 1
2 2 3 2
3 3 4 1
4 4 5 2
5 5 6 1
6 1 6 2
7 4 7 1
8 7 8 2
9 8 9 1
10 9 10 2
11 5 10 1
12 7 11 1
13 11 12 1
14 12 13 2
15 13 14 1
16 14 15 2
17 15 16 1
18 16 17 2
19 12 17 1
20 1 18 1
21 2 19 1
22 19 20 1
23 19 21 2
24 14 22 1
25 15 23 1
26 23 24 1
27 24 25 1
28 24 26 2
29 18 27 1
30 25 28 1
31 28 29 1
32 28 30 1
33 30 29 1
|